Hoth Therapeutics (HOTH) Projected to Post Quarterly Earnings on Thursday

Hoth Therapeutics (NASDAQ:HOTH) is expected to post its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect Hoth Therapeutics to post earnings of ($0.39) per share for the quarter.

Hoth Therapeutics Trading Down 2.8 %

HOTH stock opened at $1.04 on Wednesday. The business has a 50 day simple moving average of $1.16 and a 200-day simple moving average of $1.01. Hoth Therapeutics has a twelve month low of $0.58 and a twelve month high of $3.80. The company has a market capitalization of $7.18 million, a P/E ratio of -0.79 and a beta of 0.84.

Analyst Ratings Changes

HOTH has been the topic of several research reports. HC Wainwright reissued a “buy” rating and issued a $4.00 target price on shares of Hoth Therapeutics in a report on Thursday, January 23rd. D. Boral Capital reissued a “buy” rating and issued a $5.00 target price on shares of Hoth Therapeutics in a research report on Monday, March 10th.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.